Dova Pharmaceuticals (NASDAQ:DOVA) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Saturday.
DOVA has been the topic of a number of other research reports. ValuEngine downgraded shares of Dova Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 10th. Zacks Investment Research upgraded shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a report on Wednesday. Leerink Swann downgraded shares of Dova Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, July 9th. Jefferies Financial Group restated a “buy” rating and set a $40.00 price target on shares of Dova Pharmaceuticals in a report on Sunday, July 15th. Finally, Raymond James assumed coverage on shares of Dova Pharmaceuticals in a report on Wednesday, August 29th. They set an “outperform” rating and a $44.00 price target on the stock. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $33.20.
Dova Pharmaceuticals stock opened at $20.27 on Friday. The firm has a market cap of $591.40 million, a PE ratio of -14.48 and a beta of 0.34. The company has a current ratio of 13.19, a quick ratio of 13.14 and a debt-to-equity ratio of 0.17. Dova Pharmaceuticals has a 1-year low of $19.52 and a 1-year high of $37.00.
In other news, CEO Alex Sapir bought 21,700 shares of the company’s stock in a transaction that occurred on Tuesday, August 14th. The shares were purchased at an average price of $22.83 per share, for a total transaction of $495,411.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 55.50% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Metropolitan Life Insurance Co. NY bought a new position in Dova Pharmaceuticals in the 2nd quarter worth $128,000. JPMorgan Chase & Co. raised its holdings in Dova Pharmaceuticals by 148.6% in the 1st quarter. JPMorgan Chase & Co. now owns 5,345 shares of the company’s stock worth $145,000 after acquiring an additional 3,195 shares during the period. Bank of America Corp DE raised its holdings in Dova Pharmaceuticals by 81.3% in the 2nd quarter. Bank of America Corp DE now owns 5,305 shares of the company’s stock worth $159,000 after acquiring an additional 2,379 shares during the period. MetLife Investment Advisors LLC bought a new position in Dova Pharmaceuticals in the 2nd quarter worth $181,000. Finally, Commonwealth Equity Services LLC bought a new position in Dova Pharmaceuticals in the 2nd quarter worth $215,000. Hedge funds and other institutional investors own 36.57% of the company’s stock.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
See Also: Market Capitalization
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.